Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 196.00p 192.00p 200.00p 196.00p 196.00p 196.00p 11,858 07:56:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 17.1 2.6 5.0 39.1 83.24

Tristel (TSTL) Latest News

More Tristel News
Tristel Takeover Rumours

Tristel (TSTL) Share Charts

1 Year Tristel Chart

1 Year Tristel Chart

1 Month Tristel Chart

1 Month Tristel Chart

Intraday Tristel Chart

Intraday Tristel Chart

Tristel (TSTL) Discussions and Chat

Tristel Forums and Chat

Date Time Title Posts
13/4/201714:01The TRISTEL story2,236.00
15/7/201513:01Tristel PLC: Cleaning up the sector340.00
03/1/201004:54tristel with charts-
14/3/200612:13MRSA cleaner246.00
13/2/200607:10TSTL with Charts & News3.00

Add a New Thread

Tristel (TSTL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-04-28 13:58:43194.103,8727,515.55O
2017-04-28 13:40:13199.761,1732,343.18O
2017-04-28 12:43:51199.767841,566.12O
2017-04-28 12:19:08199.761,9973,989.21O
2017-04-28 11:13:56194.10434842.39O
View all Tristel trades in real-time

Tristel (TSTL) Top Chat Posts

Tristel Daily Update: Tristel Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker TSTL. The last closing price for Tristel was 196p.
Tristel Plc has a 4 week average price of 184.50p and a 12 week average price of 147.50p.
The 1 year high share price is 212p while the 1 year low share price is currently 88.50p.
There are currently 42,471,417 shares in issue and the average daily traded volume is 47,591 shares. The market capitalisation of Tristel Plc is £83,243,977.32.
source: Reminder from recent IC article:- "...But we continue to like Tristel, particularly given its strong intellectual property, market leading position and opportunity to expand into the US - the world’s biggest healthcare market. Buy" Seems like drops in share price are overreaction IMO. Especially as its European and Australian Markets are far more tangible opportunities in the short term and even before considering USA potential...IMHO. Regards, Source.
rcturner2: I thought that the share price might weaken after the excitement of the results has died away, but still looking pretty robust here. The USA is the big one, if they get that right, then we will all be minted.
rcturner2: A PE of 20 is not expensive for a company that is growing this fast. The US entry is a bonus that is not priced into the share price, in my opinion.
duncan doughnut: Nice to see the constant share price rise here recently. I had my doubts when there was the director selling recently but still moving up nicely.
rcturner2: Good statement today about the approval in Australia of a new product. Nice rise in the share price against the overall market direction.
james188: Just a couple of points I picked up in discussions after the main meeting, to add to the very helpful summary provided by Glaws2 above. 1. We have yet to see a breakdown in relation to the strong H2 overseas growth, but I understand that it was reasonably evenly distributed and not due to a spike in one jurisdiction. That said, Germany was mentioned as a strong performer. 2. At the time of the December 2015 AGM, Equity Development produced a very bullish note. Amongst other things,that note referred to Tristel having come up with a "major breakthrough in household cleaners" incorporating chlorine dioxide. I think that there was some cynicism at the time - i.e. that that was hype to drive up the share price. It is certainly true that it is very early days. However, Tristel now have a working name for the product - Puffin - and have designed a prototype container/screwcap containing the Clo2 capsules, which was on display yesterday as one of the new products that is being actively developed. A fairly low cost initiative, but it will be interesting to see if it comes to anything. More generally, I was pleased to see that Tristel continue to be active in developing a range of new offerings.
source: By Equity Development:- "...In the US the process of seeking product authorisation from the FDA and EPA carries on at pace, and is on track to (hopefully) obtain approval in 12 months' time. We have duly upgraded our FY17 turnover and PBTA forecasts by +9% and +7%, to £19.5m and £3.54m respectively. Likewise, our fair value share price target climbs 8% to 135p."
nehpets81: I don't think he would be buying little chunks in dribs and drabs if he was intending to take the company private as his actions (plus the orchestrated director buying we saw a few days ago) has the effect of boosting the share price. He either sees the shares as cheap or he is trying to create a floor for the share price, I suspect a bit of both.
source: Another update from Paul Scott (turning more positive)... Regards, Source. +++++++++++++ Tristel (LON:TSTL) Share price: 108.75p (up 4.6% today) No. shares: 42.2m Market cap: £45.9m (at the time of writing, I hold a long position in this share) Director purchases - I'm really not a fan of orchestrated Director share purchases after bad news, but as mentioned recently for another company, it does seem to work in some situations anyway, in helping to reassure investors. Perhaps it works in marginal situations, where confidence is beginning to return anyway, which is how I see Tristel? I reported here on 24 Feb 2016 on Tristel's interim results, and the various factors which triggered a sharp correction in the share price. My view, when the shares were at 125p at the time of writing that report, was that the price looked "a bit too high", but that the "longer term upside still looks good". The share price subsequently dropped considerably more, and went as low as the low-mid 90p's yesterday morning. At around that level, I think it was a reasonably good purchase, so I picked up a few, more of a dabble than a conviction buy. Management webinar - I was also really impressed with the webinar that TSTL management did with Equity Development yesterday lunchtime. I watched/listened, and felt that management were open in addressing the criticisms of the slowing sales growth, and the share options charge. There's no doubt they have dropped a big clanger with a badly designed share options scheme, but I think they recognise that, and were emphatic that there would be no repetition in the next 3-5 years. Various other factors mitigate my concerns over the slowing growth rate (now 8%), such as 4% being due to currency effects, and also that low margin products have been dropped - hitting turnover, but having little to no impact on profit. Overall, I take my hat off to TSTL management for being so open with private investors, and not only holding a webinar, but also a meeting in London, open to private investors. Feedback from this has also been positive. This is outstanding stuff - if only all companies were so willing to engage with their PI shareholder base - especially when contentious issues arise. TSTL is already being rewarded with a rebound in the share price. I think the glass is slowly turning from half empty, to half full again. The upside from potential US FDA approvals is something that I'd like to stick around for, as that could be a significant catalyst for future growth. I'm not sure there is necessarily much short term upside from here, but who knows? I would have thought it might recover to say 120-130p after a while.
tmfmayn: Effortless -- "There may be a reversal of part of this cost if the share price stays below 134p - anyone know?" I am not an expert on option accounting, but I would guess that a reversal of this charge would depend on a specific provision in the option documentation that could negate the options' original vesting condition. I very much doubt there is such a provision, but we can live in hope. A reversal could also occur (I think) if the directors were to forfeit their options for some reason. The charge assumes the directors will still be around to collect these options. Any reversal would be accounted for in the relevant future period as a credit to the income statement, and the amount charged in these latest results would not be restated. It seems to me that your £848k sum is in the right ball park (perhaps there are other senior managers with the same options, to get the charge to £1m) and that TSTL has decided to charge the majority of these '30-day/134p' options during this H1 period. The original announcement cited these options would vest in October this year, and become available over three years. Perhaps management expected the charge to be expensed over a few years, not just 6 months. I should add that nobody here was complaining when the shares topped 134p for 30 days during December/January -- and yet that option grant had been known since August. I guess if a company grants options dependent on share-price performance, we have to accept there will be a P&L cost when the share price goes up! It will be interesting to see when senior management receive its next batch of options, and what the associated vesting conditions are.
Tristel share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170429 01:51:49